• Acetylcysteine in 3D Disease Models: Optimizing Redox Modula

  2026-05-08

  Acetylcysteine (N-acetyl-L-cysteine) unlocks precise control over oxidative stress in advanced 3D co-culture systems, enabling translational breakthroughs in chemoresistance and mucolytic research. Leveraging robust, literature-backed protocols and APExBIO’s high-purity formulation, researchers can achieve reproducible modulation of glutathione biosynthesis and ROS dynamics across oncology and respiratory models.

• Nutlin-3a (SKU A3671): Reliable MDM2 Inhibitor for Cancer Re

  2026-05-08

  This article addresses common laboratory challenges in cancer research by highlighting how Nutlin-3a (SKU A3671) enables reproducible p53 pathway activation and apoptosis induction. Drawing from literature and practical lab scenarios, it provides evidence-based guidance for assay optimization, protocol selection, and vendor reliability, ensuring researchers achieve robust and interpretable results.

• Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO): Practica

  2026-05-07

  The Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) prevents protein degradation during extraction, especially in workflows requiring compatibility with mass spectrometry. It is not suitable as a stand-alone solution for inhibiting metalloproteinases unless supplemented with EDTA. Use this reagent to maximize protein integrity in crude lysates for proteomic and biochemical analysis.

• iRhom2’s Role in Olfactory Sensory Neuron Adaptation and OR

  2026-05-07

  This study uncovers the neuron-specific function of iRhom2 in olfactory sensory neurons (OSNs), showing that iRhom2 regulates subsets of odorant receptor (OR) gene expression and activity-dependent transcriptional adaptation. These findings illuminate the molecular feedback mechanisms underlying olfactory plasticity, with implications for understanding GPCR-mediated signaling in sensory biology.

• EdU Flow Cytometry Assay Kits (Cy5): Practical Use and QC

  2026-05-06

  EdU Flow Cytometry Assay Kits (Cy5) provide a validated, non-denaturing workflow for sensitive detection of cell proliferation via S-phase DNA synthesis measurement, particularly when BrdU methods are too harsh or incompatible with multiplexing. These kits are not suitable where EdU incorporation is biologically restricted or where copper-based chemistry interferes with downstream applications.

• Modeling Stroma-Driven Chemoresistance in Pancreatic Cancer

  2026-05-06

  Schuth et al. introduced a 3D co-culture system combining patient-derived pancreatic tumor organoids and matched cancer-associated fibroblasts, revealing how stromal interactions foster chemoresistance. This study advances personalized oncology by enabling mechanistic investigations of tumor-stroma crosstalk impacting drug response.

• Boc-D-FMK in Precision Apoptosis Research: Protocols & Innov

  2026-05-05

  Explore how Boc-D-FMK, a leading pan-caspase inhibitor, empowers advanced apoptosis research with precise protocol guidance and fresh insight from recent pharmacogenomic advances. Uncover practical, evidence-backed strategies and nuanced experimental considerations unique to this article.

• Targeted mRNA Nanoparticles Restore BBB After Ischemic Strok

  2026-05-05

  This study introduces a lipid nanoparticle platform for targeted delivery of mRNA encoding interleukin-10 (mIL-10) to the ischemic brain, promoting microglial polarization and restoring the blood-brain barrier (BBB) post-stroke. The findings highlight a feedback mechanism that enhances neuroprotection and extends the therapeutic window in mouse models of ischemic stroke.

• FLT3-TAZ Signaling Drives Drug Resistance in BP-CML

  2026-05-04

  Shin et al. (2023) reveal that aberrant FLT3 signaling underlies drug resistance in blast phase chronic myeloid leukemia (BP-CML), defining a new FLT3+ BP-CML subgroup with poor prognosis. The study proposes targeting the FLT3-JAK-STAT3-TAZ-TEAD-CD36 axis to overcome resistance, with translational relevance for combinatorial TKI therapies.

• Rapamycin (Sirolimus): Advanced Workflows for mTOR Inhibitio

  2026-05-04

  Rapamycin (Sirolimus) is the gold-standard mTOR inhibitor for dissecting cell signaling, immunosuppression, and mitochondrial disease mechanisms. This article provides actionable workflow enhancements and troubleshooting guidance, enabling reproducible, high-impact experiments in cancer and immunology research.

• Dual Metabolic Reprogramming Enhances Ferroptosis in TNBC

  2026-05-03

  This study pioneers a metal-polyphenol nanoplatform that co-targets iron and lipid metabolism to overcome resistance in ferroptosis-based therapy for triple-negative breast cancer (TNBC). By integrating dual DHODH and DGAT1 inhibition, the work reveals new compensatory resistance mechanisms and proposes a synergistic strategy to enhance therapeutic efficacy.

• Norepinephrine to Angiotensin II Conversion in Vasodilatory

  2026-05-02

  This article reviews a post-hoc analysis of the ARAMIS trial, which provides the first robust clinical estimate of the norepinephrine to angiotensin II conversion dose ratio in vasodilatory hypotension. These findings offer clarity for dose equivalence in critical care research and inform the design of future studies on angiotensin II and related signaling pathways.

• O-GlcNAcylation Links Wnt Signaling to Aerobic Glycolysis in

  2026-05-01

  This study reveals that O-GlcNAcylation is a critical mediator of Wnt-stimulated bone formation by rewiring glucose metabolism in osteoblasts. The findings illuminate how metabolic post-translational modifications intersect with canonical signaling pathways during osteogenesis, with implications for both basic bone biology and therapeutic intervention.

• Acetylcysteine in Precision Tumor-Stroma Modeling: Innovatio

  2026-05-01

  Acetylcysteine (N-acetyl-L-cysteine) advances precision modeling of oxidative stress and chemoresistance by integrating stromal interactions. Discover unique protocol parameters, mechanistic insights, and a critical evaluation of 3D co-culture applications.

• EdU Flow Cytometry Assay Kits (Cy5): Technical Workflow Guid

  2026-04-30

  The EdU Flow Cytometry Assay Kits (Cy5) address the need for sensitive, reproducible detection of S-phase DNA synthesis and cell proliferation in flow cytometry workflows. By using copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry, the kit circumvents common pitfalls of BrdU-based methods, such as DNA denaturation and poor multiplexing compatibility. This product is suitable for research applications in cell cycle analysis, genotoxicity, and pharmacodynamic studies, but is not designed for clinical diagnostics or in vivo labeling.

539 records 18/36 page Previous Next First page 上5页 1617181920 下5页 Last page